Best Sellers
Petide/Insulin Injection Pen (Reusable)
£25.99Reusable Insulin/Peptide Pen Injector
- PRECISION DOSE CONTROL:
Smooth adjustable dial for accurate, consistent dosing every time. - COMPATIBLE WITH 3ml CARTRIDGES:
Designed to fit standard refill cartridges for ease of use. - REUSABLE AND DURABLE DESIGN:
Built with high-quality materials for long-term reliability - COMPACT AND PORTABLE:
The slim, lightweight design of both the pen and case makes this kit ideal for travel, daily carry, or discreet storage in a bag or backpack.
Retatrutide (Pen)
Price range: £49.99 through £113.99Retatrutide
Metabolics & GLP-1 — Triple Agonist
GIP/GLP-1/GCG triple agonist peptide
Retatrutide is an investigational once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors (triple G). In the Phase II SURMOUNT dose-finding trial, 12 mg weekly produced mean body weight loss of 24.2% at 48 weeks — the highest reported for any pharmacological agent in a controlled trial.
Mechanism:
GIP + GLP-1 + glucagon triple agonist
Stage:
Phase III trials (as of 2026)
Peak Phase II Weight Loss:
24.2% at 48 weeks
Retatrutide (Vial)
Price range: £58.99 through £92.99Retatrutide
Metabolics & GLP-1 — Triple Agonist
GIP/GLP-1/GCG triple agonist peptide
Retatrutide is an investigational once-weekly triple agonist of the GIP, GLP-1, and glucagon receptors (triple G). In the Phase II SURMOUNT dose-finding trial, 12 mg weekly produced mean body weight loss of 24.2% at 48 weeks — the highest reported for any pharmacological agent in a controlled trial.
Mechanism:
GIP + GLP-1 + glucagon triple agonist
Stage:
Phase III trials (as of 2026)
Peak Phase II Weight Loss:
24.2% at 48 weeks
Selank
Price range: £33.99 through £41.99mgSelank
Neuropeptide — CNS & Mood Tuftsin-analogue anxiolytic peptide Selank is a synthetic heptapeptide analogue of tuftsin developed at the Institute of Molecular Genetics, Moscow. Studied as an anxiolytic, nootropic, and immunomodulator with a favourable safety profile and no observed dependence in animal studies — distinguishing it from classical benzodiazepines. Origin: Tuftsin analogue Developer: IMGenetika, Moscow Status: Approved Russia/Ukraine
Semax
Price range: £36.99 through £48.99Semax
Neuropeptide — ACTH Analogue Semax
A synthetic heptapeptide analogue of ACTH(4-7) developed in Russia and approved there for cognitive enhancement, stroke recovery, and neuroprotection.
It upregulates BDNF and NGF expression, producing sustained cognitive benefits beyond its short plasma half-life.
- Origin: ACTH(4-7) analogue
- Status: Approved Russia — nootropic/stroke
- Key mechanism: BDNF & NGF upregulation
Sermorelin
Price range: £28.99 through £40.99Sermorelin
Hormonal — GHRH Analogue Sermorelin is a truncated 29-amino-acid fragment of human GHRH (GHRH 1-29) that retains full biological activity of the native hormone. It was formerly marketed as Geref for diagnostic and paediatric growth hormone deficiency use before being discontinued commercially, and remains one of the most extensively studied GH secretagogues. Target: GHRH receptor Structure: GHRH(1-29) fragment Half-Life: ~10–20 minutes
SLU-PP-332
£79.99SLU-PP-332
Metabolic — Exercise Mimetic / ERR Agonist
Synthetic ERRα/β/γ pan-agonist · small molecule
SLU-PP-332 is a first-in-class synthetic pan-agonist of the oestrogen-related receptor (ERR) family — ERRα, ERRβ, and ERRγ. Developed at Saint Louis University, it activates the same nuclear receptor transcription factors as aerobic exercise, producing measurable improvements in endurance, fat oxidation, and metabolic health in preclinical models without physical activity. It represents one of the most promising “exercise mimetic” compounds in current research.
Class
ERRα/β/γ pan-agonist — small molecule
Developer
Saint Louis University (Bhatt lab)
Stage
Preclinical — 2023/24 landmark studies
SS-31
Price range: £59.99 through £179.99SS-31
Metabolic — Mitochondria-Targeted Peptide SS-31 (also studied as elamipretide)
A small, cell-permeable tetrapeptide that selectively concentrates in the inner mitochondrial membrane.
By binding cardiolipin, it stabilises mitochondrial cristae structure and reduces excess reactive oxygen species production, making it a widely studied tool compound in mitochondrial dysfunction research.
- Target: Cardiolipin (inner mitochondrial membrane)
- Class: Mitochondria-targeted tetrapeptide
- Primary Research Focus: Mitochondrial function & oxidative stress
TB-500
Price range: £17.99 through £71.99mgTB-500
Bioregulator — Thymosin β4 Fragment Actin-sequestering regenerative peptide TB-500 is a synthetic fragment of thymosin beta-4, retaining the key G-actin-sequestering domain responsible for its regenerative properties. Studied particularly for cardiac, skeletal muscle, ocular, and tendon repair. Source Protein: Thymosin β4 (Tβ4) Key Mechanism: Actin sequestration Molecular Weight: ~860 Da (fragment)
Tesamorelin
Price range: £22.99 through £90.99Tesamorelin
Hormonal — GHRH Analogue Tesamorelin
An FDA-approved synthetic GHRH analogue (Egrifta®) for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy.
It is unique among GH-axis peptides in having genuine regulatory approval, and its clinical data provides high-quality evidence for its mechanism and effects on body composition.
- Approval: FDA 2010 (Egrifta®)
- Indication: HIV lipodystrophy — visceral fat
- Half-Life: ~26 minutes
Thymosin Alpha-1
Price range: £41.99 through £53.99Thymosin Alpha-1
Immunomodulator — Thymic Peptide Thymosin Alpha-1 (Tα1)
A naturally occurring 28-amino-acid peptide derived from the thymus gland, studied for its ability to modulate both innate and adaptive immune responses.
Marketed in over 35 countries as Zadaxin for chronic hepatitis B/C and as an immune adjuvant, it has one of the most extensive clinical safety records of any immunomodulatory peptide.
- Origin:
Thymic peptide fragment - Clinical Use:
Zadaxin (hepatitis B/C, immune support) - Primary Research Focus:
Immune modulation
Tirzepatide (Pen)
Price range: £54.99 through £74.99Tirzepatide
Metabolics & GLP-1 — GIP + GLP-1 Dual Agonist
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity. Clinical trials demonstrate superior weight loss compared to semaglutide, with up to 22.5% mean body weight reduction at 15 mg weekly dosing.
